Sponsored Content
Novartis Opens Second Biotech Facility in Austria
The pharmaceutical company Novartis has commissioned its second state-of-the-art cell culture facility for the production of monoclonal antibodies in Kundl (Kufstein district). The opening of the facility, which has been invested in with a total of €500 million, along with its sister facility in Schaftenau (Kufstein district), which opened in June 2024, is seen as a strong signal for the Austrian life sciences sector. With this expansion, Novartis is creating around 100 new jobs in Kundl and strengthening its global production capacity.
The pharmaceutical company Novartis has opened its second cell culture facility for monoclonal antibodies in Kundl. / Picture: © Novartis
The investment in Tyrol, which will enable an impressive annual fermentation volume of 1.8 million liters in Kundl, is intended to ensure the reliable supply of vital medicines to the global market. As Steffen Lang, President of Operations at Novartis, emphasized, the group will thus continue to operate stably and employ 3,300 people across Austria, with sales of 1.9 billion euros in…
or Log In
Fast News Search